Cyient Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 5, 2025, 3:36 pm

Competitors of Cyient Ltd

All Competitor Stocks of Cyient Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:25 pm

Below is a detailed analysis of the quarterly data for Cyient Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,712.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,909.00 Cr. (Mar 2025) to 1,712.00 Cr., marking a decrease of 197.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,484.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,611.00 Cr. (Mar 2025) to 1,484.00 Cr., marking a decrease of 127.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 228.00 Cr.. The value appears to be declining and may need further review. It has decreased from 298.00 Cr. (Mar 2025) to 228.00 Cr., marking a decrease of 70.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 13.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 70.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 70.00 Cr., marking an increase of 29.00 Cr..
• For Interest, as of Jun 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 19.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 68.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 68.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 214.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2025) to 214.00 Cr., marking a decrease of 38.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
• For Net Profit, as of Jun 2025, the value is 157.00 Cr.. The value appears to be declining and may need further review. It has decreased from 186.00 Cr. (Mar 2025) to 157.00 Cr., marking a decrease of 29.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 13.85. The value appears to be declining and may need further review. It has decreased from 15.35 (Mar 2025) to 13.85, marking a decrease of 1.50.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:28 am

Growth

Last Updated: September 5, 2025, 2:25 am

Balance Sheet

Last Updated: July 25, 2025, 3:22 pm

Below is a detailed analysis of the balance sheet data for Cyient Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 56.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 56.00 Cr..
• For Reserves, as of Mar 2025, the value is 5,254.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,203.00 Cr. (Mar 2024) to 5,254.00 Cr., marking an increase of 1,051.00 Cr..
• For Borrowings, as of Mar 2025, the value is 513.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 788.00 Cr. (Mar 2024) to 513.00 Cr., marking a decrease of 275.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,798.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,883.00 Cr. (Mar 2024) to 1,798.00 Cr., marking a decrease of 85.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 7,621.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,928.00 Cr. (Mar 2024) to 7,621.00 Cr., marking an increase of 693.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,929.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,826.00 Cr. (Mar 2024) to 2,929.00 Cr., marking an increase of 103.00 Cr..
• For CWIP, as of Mar 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2024) to 79.00 Cr., marking an increase of 22.00 Cr..
• For Investments, as of Mar 2025, the value is 502.00 Cr.. The value appears strong and on an upward trend. It has increased from 436.00 Cr. (Mar 2024) to 502.00 Cr., marking an increase of 66.00 Cr..
• For Other Assets, as of Mar 2025, the value is 4,112.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,609.00 Cr. (Mar 2024) to 4,112.00 Cr., marking an increase of 503.00 Cr..
• For Total Assets, as of Mar 2025, the value is 7,621.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,928.00 Cr. (Mar 2024) to 7,621.00 Cr., marking an increase of 693.00 Cr..

Notably, the Reserves (5,254.00 Cr.) exceed the Borrowings (513.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Cyient Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 55.95. This value is within the healthy range. It has decreased from 62.24 (Mar 24) to 55.95, marking a decrease of 6.29.
• For Diluted EPS (Rs.), as of Mar 25, the value is 55.51. This value is within the healthy range. It has decreased from 61.71 (Mar 24) to 55.51, marking a decrease of 6.20.
• For Cash EPS (Rs.), as of Mar 25, the value is 82.92. This value is within the healthy range. It has decreased from 87.34 (Mar 24) to 82.92, marking a decrease of 4.42.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 478.32. It has increased from 410.53 (Mar 24) to 478.32, marking an increase of 67.79.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 478.32. It has increased from 410.53 (Mar 24) to 478.32, marking an increase of 67.79.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 663.10. It has increased from 643.89 (Mar 24) to 663.10, marking an increase of 19.21.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 111.70. This value is within the healthy range. It has decreased from 123.31 (Mar 24) to 111.70, marking a decrease of 11.61.
• For PBIT / Share (Rs.), as of Mar 25, the value is 87.63. This value is within the healthy range. It has decreased from 99.28 (Mar 24) to 87.63, marking a decrease of 11.65.
• For PBT / Share (Rs.), as of Mar 25, the value is 79.27. This value is within the healthy range. It has decreased from 82.74 (Mar 24) to 79.27, marking a decrease of 3.47.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 58.85. This value is within the healthy range. It has decreased from 63.31 (Mar 24) to 58.85, marking a decrease of 4.46.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 55.47. This value is within the healthy range. It has decreased from 61.51 (Mar 24) to 55.47, marking a decrease of 6.04.
• For PBDIT Margin (%), as of Mar 25, the value is 16.84. This value is within the healthy range. It has decreased from 19.15 (Mar 24) to 16.84, marking a decrease of 2.31.
• For PBIT Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. It has decreased from 15.41 (Mar 24) to 13.21, marking a decrease of 2.20.
• For PBT Margin (%), as of Mar 25, the value is 11.95. This value is within the healthy range. It has decreased from 12.84 (Mar 24) to 11.95, marking a decrease of 0.89.
• For Net Profit Margin (%), as of Mar 25, the value is 8.87. This value is within the healthy range. It has decreased from 9.83 (Mar 24) to 8.87, marking a decrease of 0.96.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.36. This value is within the healthy range. It has decreased from 9.55 (Mar 24) to 8.36, marking a decrease of 1.19.
• For Return on Networth / Equity (%), as of Mar 25, the value is 11.59. This value is below the healthy minimum of 15. It has decreased from 16.03 (Mar 24) to 11.59, marking a decrease of 4.44.
• For Return on Capital Employeed (%), as of Mar 25, the value is 15.37. This value is within the healthy range. It has decreased from 20.61 (Mar 24) to 15.37, marking a decrease of 5.24.
• For Return On Assets (%), as of Mar 25, the value is 8.00. This value is within the healthy range. It has decreased from 9.74 (Mar 24) to 8.00, marking a decrease of 1.74.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.01, marking a decrease of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. It has decreased from 0.10 (Mar 24) to 0.04, marking a decrease of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.00. It has decreased from 1.05 (Mar 24) to 1.00, marking a decrease of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.15 (Mar 24) to 3.03, marking an increase of 0.88.
• For Quick Ratio (X), as of Mar 25, the value is 2.60. This value exceeds the healthy maximum of 2. It has increased from 1.86 (Mar 24) to 2.60, marking an increase of 0.74.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 4. It has decreased from 2.19 (Mar 24) to 2.18, marking a decrease of 0.01.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 53.59. This value exceeds the healthy maximum of 50. It has increased from 44.81 (Mar 24) to 53.59, marking an increase of 8.78.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 37.37. This value is within the healthy range. It has increased from 32.22 (Mar 24) to 37.37, marking an increase of 5.15.
• For Earning Retention Ratio (%), as of Mar 25, the value is 46.41. This value is within the healthy range. It has decreased from 55.19 (Mar 24) to 46.41, marking a decrease of 8.78.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 62.63. This value is within the healthy range. It has decreased from 67.78 (Mar 24) to 62.63, marking a decrease of 5.15.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 11.80 (Mar 24) to 13.36, marking an increase of 1.56.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.04. This value is within the healthy range. It has increased from 7.64 (Mar 24) to 8.04, marking an increase of 0.40.
• For Enterprise Value (Cr.), as of Mar 25, the value is 13,380.90. It has decreased from 21,896.86 (Mar 24) to 13,380.90, marking a decrease of 8,515.96.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.82. This value is within the healthy range. It has decreased from 3.06 (Mar 24) to 1.82, marking a decrease of 1.24.
• For EV / EBITDA (X), as of Mar 25, the value is 10.79. This value is within the healthy range. It has decreased from 16.00 (Mar 24) to 10.79, marking a decrease of 5.21.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.91. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 1.91, marking a decrease of 1.19.
• For Retention Ratios (%), as of Mar 25, the value is 46.40. This value is within the healthy range. It has decreased from 55.18 (Mar 24) to 46.40, marking a decrease of 8.78.
• For Price / BV (X), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.20 (Mar 24) to 2.64, marking a decrease of 2.56.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.91. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 1.91, marking a decrease of 1.19.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness